Short answer
Hereditary arrhythmia panel testing looks for variants linked to inherited heart-rhythm conditions such as long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and some related channelopathies. It is most useful when the ECG, fainting pattern, exercise-triggered symptoms, family history of sudden death, or a known familial variant makes the question specific enough to answer.
When a panel is useful
| Scenario | How testing helps | What still matters |
|---|---|---|
| Suspected inherited rhythm syndrome | A pathogenic variant can support diagnosis and guide family testing. | ECG, symptom pattern, and medication review still matter. |
| Known familial variant | Targeted cascade testing can quickly sort affected relatives from unaffected relatives. | Relatives may still need cardiac screening. |
| Sudden unexplained death in the family | A panel can help after phenotyping points to an inherited arrhythmia. | Broad testing without context can return uncertain results. |
What the panel can and cannot do
Panel testing can identify a pathogenic variant, but it can also return a variant of uncertain significance, a negative result, or a finding that does not fully explain the rhythm problem. A negative result does not erase a clinical diagnosis. A positive result does not replace ECGs, exercise testing, Holter or event monitoring, or a cardiac genetics evaluation.
Why clinical context comes first
The best arrhythmia testing path starts with the phenotype. Long QT, Brugada, and CPVT each have different triggers and different testing logic. A consumer raw DNA file is not a substitute for a clinical panel ordered and interpreted in context.
What a result means
| Result | What it suggests | What usually comes next |
|---|---|---|
| Pathogenic / likely pathogenic variant | Can support the suspected syndrome and family screening. | Cardiac genetics follow-up and targeted testing for relatives. |
| Variant of uncertain significance | Not enough evidence to call it disease-causing. | Do not treat the VUS as a confirmed diagnosis on its own. |
| Negative panel | No reportable variant was found on that panel. | Clinical evaluation may still support an inherited rhythm diagnosis. |
Questions to ask
- What rhythm syndrome is actually suspected from the ECG and symptoms?
- Does the panel include the genes most relevant to the phenotype?
- How will a variant of uncertain significance be handled?
- Who in the family should get targeted testing and cardiac screening if a pathogenic variant is found?
FAQ
Do I need a broad panel if I already have a long QT diagnosis?
Often the clinical question comes first, and the test should be matched to the syndrome rather than ordered as a generic screen.
Can a negative panel rule out an inherited arrhythmia?
No. Some people have a clinical diagnosis even when panel testing is negative.
What if the result is a VUS?
A VUS is not a confirmed disease-causing answer and should not be treated as one without more evidence.
Should relatives get tested automatically?
Usually only after a pathogenic familial variant is identified or a cardiology/genetics team recommends targeted screening.
Can the panel tell me if a medication is safe?
Not by itself. Medication safety still depends on the syndrome, ECG findings, symptoms, and clinician guidance.
Why not just use a consumer DNA report?
Because clinical arrhythmia interpretation needs variant curation, phenotype matching, and family follow-up that consumer reports often do not provide.
Related guides: long QT syndrome genetic testing, genetic testing for hereditary heart disease, hereditary cardiomyopathy genetic testing, and genetic counselor guide.